MCID: GLL022
MIFTS: 58

Guillain-Barre Syndrome malady

Categories: Rare diseases, Neuronal diseases, Immune diseases

Aliases & Classifications for Guillain-Barre Syndrome

About this section

Aliases & Descriptions for Guillain-Barre Syndrome:

Name: Guillain-Barre Syndrome 11 46 24 13 48 36 66
Guillain-Barré Syndrome 46 24 47
Gbs 46 24 2
Acute Inflammatory Demyelinating Polyneuropathy 46 66
Acute Inflammatory Polyneuropathy 46 24
Fisher Syndrome 24 47
Acute Inflammatory Demyelinating Polyradiculoneuropathy 46
Acute Autoimmune Peripheral Neuropathy 46
Landry-Guillain-Barre-Strohl Syndrome 46
Acute Immune-Mediated Polyneuropathy 46
Acute Postinfectious Polyneuropathy 11
Acute Infective Polyneuritis Nos 11
Group B Streptococcal Infection 66
 
Guillain-Barré-Strohl Syndrome 46
Landry-Guillain-Barre Syndrome 24
Acute Inflammatory Neuropathy 46
Acute Infectious Polyneuritis 24
Post-Infectious Polyneuritis 11
Acute Infective Polyneuritis 11
Landry's Ascending Paralysis 46
Postinfectious Polyneuritis 11
Post-Infective Polyneuritis 46
Acute Autoimmune Neuropathy 66
Acute Inf. Polyneuritis 11
Miller Fisher Syndrome 66
Infectious Neuronitis 11

Classifications:



External Ids:

Disease Ontology11 DOID:12842
ICD1028 G61.0
NCIt43 C116345

Summaries for Guillain-Barre Syndrome

About this section
NIH Rare Diseases:46 Guillain-barré syndrome is a rare disorder in which the body's immune system attacks part of the peripheral nervous system. symptoms include muscle weakness, numbness, and tingling sensations, which can increase in intensity until the muscles cannot be used at all. usually guillain-barré syndrome occurs a few days or weeks after symptoms of a viral infection. occasionally, surgery or vaccinations will trigger the syndrome. it remains unclear why only some people develop guillain-barré syndrome but there may be a genetic predisposition in some cases. diagnosed patients should be admitted to a hospital for early treatment. there is no cure for guillain-barré syndrome, but treatments such as plasma exchange (plasmapheresis) and high dose immunoglobulins may reduce the severity and duration of symptoms. recovery can take as little as a few days to as long as a few years. about 30% of those with guillain-barré syndrome have residual weakness. a small number may suffer a relapse many years after the initial attack. last updated: 1/16/2016

MalaCards based summary: Guillain-Barre Syndrome, also known as guillain-barré syndrome, is related to membranous glomerulonephritis and myelitis, and has symptoms including back pain, headache and pain. An important gene associated with Guillain-Barre Syndrome is PMP22 (Peripheral Myelin Protein 22), and among its related pathways are Neural Crest Differentiation and Adipocytokine signaling pathway. The drug immunoglobulins, intravenous has been mentioned in the context of this disorder. Affiliated tissues include brain, spinal cord and testes, and related mouse phenotypes are liver/biliary system and neoplasm.

Disease Ontology:11 An autoimmune disease of peripheral nervous system that causes body's immune system to attack part of the peripheral nervous system.

MedlinePlus:36 Guillain-barre syndrome is a rare disorder that causes your immune system to attack your peripheral nervous system (pns). the pns nerves connect your brain and spinal cord with the rest of your body. damage to these nerves makes it hard for them to transmit signals. as a result, your muscles have trouble responding to your brain. no one knows what causes the syndrome. sometimes it is triggered by an infection, surgery, or a vaccination. the first symptom is usually weakness or a tingling feeling in your legs. the feeling can spread to your upper body. in severe cases, you become almost paralyzed. this is life-threatening. you might need a respirator to breathe. symptoms usually worsen over a period of weeks and then stabilize. guillain-barre can be hard to diagnose. possible tests include nerve tests and a spinal tap. most people recover. recovery can take a few weeks to a few years. treatment can help symptoms, and may include medicines or a procedure called plasma exchange. nih: national institute of neurological disorders and stroke

CDC:2 Group B Streptococcus (group B strep) is a type of bacteria that causes illness in people of all ages. Also known as GBS, group B strep disease is the most common cause of severe infections in newborns that can be deadly, but it can be prevented.

NINDS:47 Miller Fisher syndrome is a rare, acquired nerve disease that is considered to be a variant of Guillain-Barr

Genetics Home Reference:24 Guillain-Barré syndrome is an autoimmune disorder that affects the nerves. Autoimmune disorders occur when the immune system malfunctions and attacks the body's own tissues and organs. In Guillain-Barré syndrome, the immune response damages peripheral nerves, which are the nerves that connect the central nervous system (the brain and spinal cord) to the limbs and organs. Specifically, the immune response affects a particular part of peripheral nerves called axons, which are the extensions of nerve cells (neurons) that transmit nerve impulses. Guillain-Barré syndrome can affect the neurons that control muscle movement (motor neurons); the neurons that transmit sensory signals such as pain, temperature, and touch (sensory neurons); or both. As a result, affected individuals can experience muscle weakness or lose the ability to feel certain sensations.

Wikipedia:69 Guillain–Barré syndrome (GBS) is a rapid-onset muscle weakness caused by the immune system damaging... more...

Related Diseases for Guillain-Barre Syndrome

About this section

Diseases related to Guillain-Barre Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 329)
idRelated DiseaseScoreTop Affiliating Genes
1membranous glomerulonephritis30.3CD40LG, CD79A
2myelitis29.2CD40LG, MBP, PMP22, TNF, TNFRSF1A
3systemic lupus erythematosus27.2ALB, CD40LG, CD79A, HLA-DQA1, HLA-DQB1, HLA-DRB1
4pharyngeal-cervical-brachial variant of guillain-barré syndrome12.4
5paraparetic variant of guillain-barré syndrome12.3
6miller fisher syndrome11.8
7neuropathy, inflammatory demyelinating11.7
8osteogenesis imperfecta congenita, microcephaly, and cataracts10.8HLA-DQA1, HLA-DQB1
9chronic inflammatory demyelinating polyneuropathy10.8
10common variable immunodeficiency10.8HLA-DRB1, TNF
11fruit allergy10.8HLA-DQB1, HLA-DRB1
12weber syndrome10.7HLA-DRB1, TNF
13quinquaud's decalvans folliculitis10.7HLA-DQB1, HLA-DRB1
14dysautonomia10.7
15pediatric systemic lupus erythematosus10.7HLA-DQB1, HLA-DRB1
16plantar nerve lesion10.7PMP22, TNF
17vitreoretinochoroidopathy dominant10.7HLA-DQB1, HLA-DRB1
18hereditary orotic aciduria without megaloblastic anaemia10.7MPZ, PMP22
19autonomic dysfunction10.7
20limb dystonia10.7HLA-DQB1, HLA-DRB1
21headache10.7MPZ, PMP22
22spondylarthropathy10.7HLA-DQB1, HLA-DRB1
23multiple sclerosis 510.7TNF, TNFRSF1A
24secondary hypertrophic osteoarthropathy10.7MPZ, PMP22
25rhizomelic pseudopolyarthritis10.6HLA-DRB1, TNF
26mitochondrial encephalomyopathy10.6HLA-DQB1, HLA-DRB1
27epstein-barr virus hepatitis10.6HLA-DRB1, TNF
28charcot-marie-tooth neuropathy type 2e/1f10.6MPZ, PMP22
29uveoparotid fever10.6TNF, TNFRSF1B
30krieble bixler syndrome10.6HLA-DQB1, HLA-DRB1, TNF
31peripheral t-cell lymphoma10.6HLA-DQB1, HLA-DRB1, TNF
32lipodermatosclerosis10.6HLA-DQB1, HLA-DRB1, TNF
33abdominal chemodectomas with cutaneous angiolipomas10.6HLA-DRB1, TNF
34idiopathic central precocious puberty10.6HLA-DQB1, HLA-DRB1, TNF
35sensorineural hearing loss10.6HLA-DQB1, HLA-DRB1, TNF
36wolffian duct adenocarcinoma10.6HLA-DQA1, HLA-DQB1, HLA-DRB1
37panuveitis10.6HLA-DQA1, HLA-DRB1, TNF
38hyperthyroxinemia10.6HP, TNF
39autoinflammation, lipodystrophy, and dermatosis syndrome10.5HLA-DQA1, HLA-DQB1, HLA-DRB1
40aseptic osteitis10.5HLA-DQA1, HLA-DQB1, HLA-DRB1
41oculogyric crisis10.5HLA-DQA1, HLA-DQB1, HLA-DRB1
42stone in bladder diverticulum10.5TNF, TNFRSF1B
43multicentric castleman disease10.5HLA-DQA1, HLA-DQB1, HLA-DRB1
44neuromuscular disease10.5TNF, TNFRSF1B
45histoplasmosis pericarditis10.5HLA-DQA1, HLA-DRB1, TNF
46adult malignant hemangiopericytoma10.5HLA-DQA1, HLA-DRB1, TNF
47calcinosis10.5CD40LG, PMP22
48anal canal adenocarcinoma10.5MPZ, PMP22
49intermittent proptosis10.5HLA-DQA1, HLA-DRB1, TNF
50keratoconjunctivitis sicca10.5CD40LG, TNF

Comorbidity relations with Guillain-Barre Syndrome via Phenotypic Disease Network (PDN):


Hypertension, EssentialRespiratory Failure
Acute Cystitis

Graphical network of the top 20 diseases related to Guillain-Barre Syndrome:



Diseases related to guillain-barre syndrome

Symptoms for Guillain-Barre Syndrome

About this section

UMLS symptoms related to Guillain-Barre Syndrome:


back pain, headache, pain, sciatica, seizures, syncope, tremor, chronic pain, muscle weakness, vertigo/dizziness, sleeplessness, cerebellar ataxia, ophthalmoplegia, neuralgia

Drugs & Therapeutics for Guillain-Barre Syndrome

About this section

Drugs for Guillain-Barre Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
4-AminopyridinePhase 267504-24-51727
Synonyms:
.gamma.-Aminopyridine
275875_ALDRICH
36687_FLUKA
36687_RIEDEL
4 AP
4 Aminopyridine
4 Aminopyridine Sustained Release
4-AP
4-Aminopyridine
4-Aminopyridine 10
4-Aminopyridine Sustained Release
4-Pyridinamine
4-Pyridylamine
4-aminopyridine
5-22-09-00106 (Beilstein Handbook Reference)
504-24-5
A 0152
A0414
A78403_ALDRICH
AB1004971
AC-907/25014071
AC1L1C3R
AC1Q52BM
AI3-52547
AKOS000119896
Amaya
Amino-4 pyridine
Amino-4-Pyridine
Ampydin
Ampyra
Avitrol
Avitrol 200
BB_SC-6974
BRN 0105782
BSPBio_001562
Bio1_000353
Bio1_000842
Bio1_001331
Bio2_000282
Bio2_000762
C13728
C5H6N2
CHEBI:34385
CHEMBL284348
CID1727
Caswell No. 038
Compound 1861
D015761
D04127
Dalfampridine
DivK1c_000572
EINECS 207-987-9
EL-970
EPA Pesticide Chemical Code 069201
EU-0100032
FT-0083754
Fampridina
Fampridine
Fampridine (USAN/INN)
Fampridine SR
Fampridine [USAN:INN]
Fampridine-PR
Fampridine-SR
Fampridinum
HC150041
HMS1361O04
HMS1791O04
HMS1921H15
HMS1989O04
HMS2092F05
HMS501M14
HSDB 6037
IDI1_000572
IDI1_034032
InChI=1/C5H6N2/c6-5-1-3-7-4-2-5/h1-4H,(H2,6,7
KBio1_000572
 
KBio2_000282
KBio2_000635
KBio2_002850
KBio2_003203
KBio2_005418
KBio2_005771
KBio3_000563
KBio3_000564
KBio3_001888
KBioGR_000282
KBioGR_001505
KBioSS_000282
KBioSS_000635
LS-130202
Lopac-A-0152
Lopac0_000032
MLS000069400
Mi-W-3
MolPort-000-146-022
N07XX07
NCGC00015009-01
NCGC00015009-03
NCGC00015009-12
NCGC00024890-01
NCGC00024890-02
NCGC00024890-03
NCGC00024890-04
NCGC00024890-05
NCGC00024890-06
NCGC00024890-07
NCGC00024890-08
NCGC00024890-09
NCGC00024890-10
NINDS_000572
NSC 15041
NSC15041
Neurelan
Neurelan (TN)
P-Aminopyridine
PYRIDINE,4-AMINO
Philips 1861
Phillips 1861
Pimadin (free base)
Prc 1237
Pymadin
Pymadine
RCRA waste no. P008
SDCCGMLS-0066228.P001
SMR000058211
SPBio_001486
SPECTRUM1501130
STK298717
Spectrum2_001413
Spectrum3_000914
Spectrum4_001013
Spectrum5_001501
Spectrum_000155
Sustained Release, 4-Aminopyridine
TL8003344
Tocris-0940
UNII-BH3B64OKL9
UPCMLD-DP125
UPCMLD-DP125:001
VMI 10-3
VMI 103
VMI-10-3
VMI-103
VMI103
WLN: T6NJ DZ
[J.Pharmacol.Exp.Ther. 275:864 (1995)]
gamma-Aminopyridine
nchem.892-comp4
p-Aminopyridine
p-Aminopyridine [UN2671] [Poison]
p-Aminopyridine [UN2671] [Poison]
pyridin-4-amine
pyridin-4-ylamine
2
Citric Acid106377-92-9311
Synonyms:
2-Hydroxy-1,2,3-propanetricarboxylate
2-Hydroxy-1,2,3-propanetricarboxylic acid
2-Hydroxytricarballylic acid
3-Carboxy-3-hydroxypentane-1,5-dioate
3-Carboxy-3-hydroxypentane-1,5-dioic acid
Aciletten
Anhydrous citrate
Anhydrous citric acid
Chemfill
Citraclean
 
Citrate
Citretten
Citric acid
Citro
Citronensäure
E 330
Hydrocerol A
Kyselina citronova
Suby G
Uro-trainer
beta-Hydroxytricarballylate
beta-Hydroxytricarballylic acid
3
nivolumab254946414-94-4
Synonyms:
BMS-936558
 
MDX-1106
ONO-4538
nivolumab
4CitrateNutraceutical1063
5
ThiamineNutraceutical9559-43-81130
Synonyms:
100660-17-1
115461-66-0
1sbr
2-[3-[(4-amino-2-methylpyrimidin-5-yl)methyl]-4-methyl-1,3-thiazol-3-ium-5-yl]ethanol
2-[3-[(4-amino-2-methylpyrimidin-5-yl)methyl]-4-methyl-1,3-thiazol-3-ium-5-yl]ethanol chloride
3-((4-Amino-2-methyl-5-pyrimidinyl)methyl)-5-(2-hydrox yethyl)-4-methylthiazolium chloride
3-((4-Amino-2-methyl-5-pyrimidinyl)methyl)-5-(2-hydroxyethyl)-4-m- ethylthiazolium chloride, monohydrochloride
3-((4-Amino-2-methyl-5-pyrimidinyl)methyl)-5-(2-hydroxyethyl)-4-methylthiazolium chloride
3-((4-Amino-2-methyl-5-pyrimidinyl)methyl)-5-(2-hydroxyethyl)-4-methylthiazolium chloride monohydrochloride
3-(4-AMINO-2-METHYL-PYRIMIDIN-5-YLMETHYL)-5-(2-HYDROXY-ETHYL)-4-METHYL-THIAZOL-3-IUM
3-(4-AMINO-2-methyl-pyrimidin-5-ylmethyl)-5-(2-hydroxy-ethyl)-4-methyl-thiazol-3-ium
3-[(4-amino-2-methyl-5-pyrimidinyl)methyl]-5-(2-hydroxyethyl)-4-methylthiazolium chloride
3-[(4-amino-2-methylpyrimidin-5-yl)methyl]-5-(2-hydroxyethyl)-4-methyl-1,3-thiazol-3-ium
3-[(4-amino-2-methylpyrimidin-5-yl)methyl]-5-(2-hydroxyethyl)-4-methyl-1,3-thiazol-3-ium chloride
3-[(4-amino-2-methylpyrimidin-5-yl)methyl]-5-(2-hydroxyethyl)-4-methyl-1,3-thiazol-3-ium chloride hydrochloride
3[(4-Amino-2-methyl-5-pyrimidinyl)-methyl]-5-(2-hydroxyethyl)-4-methylthiazolium chloride
55463-15-5
57777-32-9
59-43-8
67-03-8
AC-11683
AC1L1ASK
AC1L1LOC
AC1LAODT
AC1Q4V9Q
AI3-18993
AKOS000668650
AR-1L8201
Aneurin
Aneurine
Antiberiberi factor
Apatate drape
Apate drops
B-Amin
BAS 00266240
BPBio1_000686
BSPBio_000622
Beatine
Bedome
Begiolan
Beivon
Benerva
Bequin
Berin
Betabion
Betalin S
Betaxin
Bethiamin
Bethiazine
Beuion
Bevitex
Bevitine
Bewon
Biamine
Bithiamin
Biuno
Bivatin
Bivita
C00378
C12H17N4OS
CCRIS 1906
CCRIS 5823
CHEBI:18385
CHEBI:33283
CHEBI:49105
CHEMBL1547
CHEMBL1588
CID1130
CID517305
CID6042
Cernevit-12
Chloride-hydrochloride salt of thiamine
Clotiamina
D08580
DB00152
EINECS 200-425-3
EINECS 200-641-8
Eskapen
Eskaphen
FEMA No. 3322
 
HSDB 220
Hybee
I14-14339
LS-3226
LT00233141
Lixa-beta
MLS001304099
Metabolin
MolPort-000-722-048
MolPort-001-920-086
MolPort-002-052-059
NChemBio.2007.13-comp10
NSC 36226
NSC36226
Oryzanin
Oryzanine
Prestwick0_000631
Prestwick1_000631
Prestwick2_000631
Prestwick3_000631
SBB058094
SMP1_000084
SMR000718788
SPBio_002841
ST095175
Slowten
THD
THIAMIN, VITAMIN B1
Thiadoxine
Thiamin
Thiamin dichloride
Thiaminal
Thiamine
Thiamine (INN)
Thiamine HCL
Thiamine [INN:BAN]
Thiamine chloride
Thiamine chloride hydrochloride
Thiamine dichloride
Thiamine hydrochloride [JAN]
Thiamine monochloride
Thiamine monohydrochloride
Thiamine, chloride
Thiamine, chloride, hydrochloride
Thiamine, monohydrochloride
Thiaminium
Thiaminium chloride hydrochloride
Thiaminum
Thiaminum [INN-Latin]
Thiamol
Thiavit
Thiazolium, 3-((4-amino-2-methyl-5-pyrimidinyl)methyl)-5-(2-hydroxyethyl)-4-m- ethyl, chloride, monohydrochloride
Thiazolium, 3-((4-amino-2-methyl-5-pyrimidinyl)methyl)-5-(2-hydroxyethyl)-4-methyl- chloride
Thiazolium, 3-((4-amino-2-methyl-5-pyrimidinyl)methyl)-5-(2-hydroxyethyl)-4-methyl- chloride (1:1)
Thiazolium, 3-((4-amino-2-methyl-5-pyrimidinyl)methyl)-5-(2-hydroxyethyl)-4-methyl-, chloride, monohydrochloride
Thiazolium, 3-((4-amino-2-methyl-5-pyrimidinyl)methyl)-5-(2-hydroxyethyl)-4-methyl-chloride
Tiamidon
Tiamina
Tiamina [INN-Spanish]
Tiaminal
TimTec1_000613
Trophite
UNII-X66NSO3N35
VIB
Vetalin S
Vinothiam
Vitamin B1
Vitamin B1 (TN)
Vitamin B1 hydrochloride (VAN)
Vitaneurin
Vitaneuron
ZINC00049153
[5-[[5-(2-hydroxyethyl)-4-methyl-1,3-thiazol-3-ium-3-yl]methyl]-2-methylpyrimidin-4-yl]azanium dichloride
bmse000274
nchembio.121-comp5
thiamin
thiamine
thiamine(1+)
thiamine(1+) ion
thiaminium
vitamin B1
vitamin b1(thiamine)

Interventional clinical trials:

(show all 36)
idNameStatusNCT IDPhase
1Postmarketing Safety Study of Q/LAIV in Subjects 2 Through 49 Years of AgeCompletedNCT01985997Phase 4
2Efficacy and Safety Study of GB-0998 for Guillain-Barré SyndromeCompletedNCT02342184Phase 3
3Additional 6-Month Safety Follow-up After Completion of Precursor Study 880801CompletedNCT01604746Phase 3
4Phase III Clinical Trial of NPB-01 in Patients With Guillain-Barré SyndromeRecruitingNCT02221271Phase 3
5Immunogenicity, Reactogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' MenACWY-TT Vaccine Administered 6 Years Post-MenC Primary Vaccination in Healthy Subjects Who Were 12-18 Months at Primary VaccinationActive, not recruitingNCT01777308Phase 3
6Study to Evaluate the Long-term Antibody Persistence of GlaxoSmithKline (GSK) Biologicals' MenACWY-TT Vaccine (GSK134612) Versus Mencevax ACWY in Healthy Adolescents and Adults and Booster Response to MenACWY-TT Vaccine Administered at 10 Years Post-primaActive, not recruitingNCT01934140Phase 3
7Early Mechanical Ventilation for Guillain Barré SyndromeCompletedNCT00167622Phase 2
8Assessment of Chronic Guillain-Barre Syndrome Improvement With Use of 4-aminopyridineCompletedNCT00056810Phase 2
9Small Volume Plasma Exchange (SVPE) for Guillain-Barré Syndrome (GBS) PatientsRecruitingNCT02780570Phase 2
10Inhibition of Complement Activation (Eculizumab) in Guillain-Barre Syndrome StudyRecruitingNCT02029378Phase 2
11JET-GBS - Japanese Eculizumab Trial for GBSActive, not recruitingNCT02493725Phase 2
12Study of GLS-5700 in Dengue Virus Seropositive AdultsRecruitingNCT02887482Phase 1
13Study of GLS-5700 in Healthy VolunteersActive, not recruitingNCT02809443Phase 1
14Intravenous Immunoglobulin (IVIG) Versus Plasma Exchange (PE) for Ventilated Children With Guillain Barre Syndrome (GBS)CompletedNCT01306578
15Prospective Study on Swallowing/Breathing Interactions in Severe Guillain Barre Syndrome.CompletedNCT01024088
16Effects of Robotic-assisted Gait Training In Non-Ambulatory Patients After Guillain-Barré SyndromeCompletedNCT02883270
17Brain Computer Interface for Communication in ICU: a Feasibility StudyCompletedNCT01005524
18Regional Citrate Anticoagulation in Plasma Exchange TreatmentCompletedNCT01370200
19Cervarix Long-term Safety SurveillanceCompletedNCT01498627
20Surveillance for Adverse Events Following Pandemic H1N1 ImmunizationCompletedNCT01289418
21Surveillance for Adverse Events Following Influenza ImmunizationCompletedNCT01318876
22Study Assessing Risk of Autoimmune Diseases in Females (9 - 25 Years) Exposed to Cervarix® in United KingdomCompletedNCT01953822
23Clinical Trial to Evaluate Magtein in Older AdultsCompletedNCT02363634
24International Guillain-Barré Syndrome Outcome StudyRecruitingNCT01582763
25sCD163 as a Potential Biomarker in Guillain- Barré SyndromeRecruitingNCT02582853
26The Changes of Cytokines in Guillain Barré Syndrome: the Correlation With Clinical Manifestations and Skin InnervationRecruitingNCT00173199
27Pattern of Use and Safety/Effectiveness of Nivolumab in Routine Oncology PracticeRecruitingNCT02847728
28Thiamin (Vitamin B1) Levels in Eating Disorder Adolescent PatientsRecruitingNCT02164487
29Safety Study of GBS Following Menactra Meningococcal VaccinationActive, not recruitingNCT00575653
30Change of Nerve Conduction Properties in IVIg Dependent NeuropathiesActive, not recruitingNCT01655394
31Comparative Autoantibody and Immunologic Cell Marker StudyEnrolling by invitationNCT02422875
32Processing Integration in Neurological Patients Using fMRINot yet recruitingNCT02722070
33Perception and Multisensory Integration in Neurological Patients Using fMRINot yet recruitingNCT01469858
34Detection of Peripheral Blood Biomarkers in Intermediate Phase Spinal Cord Injury: Correlation With Neurological and Functional Outcomes, and Comparison to Other Central and Peripheral Neurological Conditions.Not yet recruitingNCT01516385
35Gastrointestinal Transit Time in Patients With Guillain-Barré SyndromeSuspendedNCT02459808
36Randomized Study of Plasmapheresis or Human Immunoglobulin Infusion in Childhood Guillain-Barre SyndromeTerminatedNCT00004833

Search NIH Clinical Center for Guillain-Barre Syndrome

Inferred drug relations via UMLS66/NDF-RT44:

Genetic Tests for Guillain-Barre Syndrome

About this section

Anatomical Context for Guillain-Barre Syndrome

About this section

MalaCards organs/tissues related to Guillain-Barre Syndrome:

34
Brain, Spinal cord, Testes, Heart, Skin, T cells

Animal Models for Guillain-Barre Syndrome or affiliated genes

About this section

MGI Mouse Phenotypes related to Guillain-Barre Syndrome:

39 (show all 12)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053708.8ALB, HLA-DQB1, HP, TNF, TNFRSF1A, TNFRSF1B
2MP:00020068.6ALB, CD79A, HP, TNF, TNFRSF1A, TNFRSF1B
3MP:00053898.3CD40LG, HLA-DQB1, MBP, MPZ, PMP22, TNF
4MP:00053677.4ALB, CD40LG, CD79A, HLA-DQB1, HP, TNFRSF1A
5MP:00053797.4ALB, CD40LG, HLA-DQA1, HLA-DQB1, TNF, TNFRSF1A
6MP:00036317.2CD40LG, CD79A, HLA-DQB1, MBP, MPZ, PMP22
7MP:00053876.8CD40LG, CD79A, HLA-DQA1, HLA-DQB1, HP, MBP
8MP:00107686.8ALB, CD40LG, HLA-DQB1, HP, MBP, MPZ
9MP:00053846.8ALB, CD40LG, CD79A, HLA-DQB1, HP, MBP
10MP:00053766.7ALB, CD40LG, CD79A, HLA-DQB1, HP, MBP
11MP:00053976.7CD40LG, CD79A, HLA-DQA1, HLA-DQB1, HP, MBP

Publications for Guillain-Barre Syndrome

About this section

Articles related to Guillain-Barre Syndrome:

(show top 50)    (show all 164)
idTitleAuthorsYear
1
Successful treatment of Guillain-Barre syndrome by Ayurvedic treatment. (27143805)
2016
2
A Case of Visceral Autonomic Neuropathy Complicated by Guillain-Barre Syndrome Accompanied with Cyclic Vomiting Syndrome-like Disorder in a Child. (26157699)
2015
3
Guillain-Barre syndrome in acute lymphoblastic leukemia: Causal or coincidental. (25878750)
2015
4
Acute hemiplegia as a rare presentation of infantile Guillain-Barre syndrome. (25399226)
2014
5
Association between human leukocyte antigen-DR and demylinating Guillain-Barre syndrome. (25274590)
2014
6
Acute Motor-Sensory Axonal Neuropathy With Hyperreflexia in Guillain-Barre Syndrome. (24700665)
2014
7
An unusual case of Guillain-Barre syndrome following toxic shock syndrome in a burned child. (24182693)
2013
8
Guillain-Barre syndrome in Asia. (24357682)
2013
9
Simple bedside predictors of mechanical ventilation in patients with Guillain-Barre syndrome. (24378177)
2013
10
Clinically silent posterior reversible encephalopathy in Guillain-Barre syndrome. (23573560)
2013
11
An unusual case of recurrent guillain-barre syndrome of a different subtype five years after initial diagnosis. (23710387)
2013
12
Hepatitis E and Guillain-Barre syndrome. (23899686)
2013
13
Increased Guillain-Barre syndrome admissions in Shiraz, southern Iran. (24250891)
2013
14
Guillain-Barre syndrome in an adult patient with Henoch-Schonlein purpura. (23559644)
2013
15
Efficacy of low-dose intravenous cyclophosphamide in systemic lupus erythematosus presenting with Guillain-Barre syndrome-like acute axonal neuropathies: report of two cases. (23439473)
2013
16
Clinico-electrophysiological profile and predictors of functional outcome in Guillain-Barre syndrome (GBS). (24064258)
2013
17
Guillain-Barre syndrome after coronary artery bypass surgery. (22899666)
2012
18
Guillain-Barre syndrome in colorectal cancer. (22524581)
2012
19
A case of acute neurogenic weakness mimicking the axonal variant of the Guillain-Barre syndrome. (23144300)
2012
20
Prevalence of bladder dysfunction, urodynamic findings, and their correlation with outcome in Guillain-Barre syndrome. (22488834)
2012
21
No evidence of a link between influenza vaccines and Guillain-Barre syndrome-associated antiganglioside antibodies. (21955390)
2012
22
Dry beriberi mimicking Guillain-Barre syndrome as the first presenting sign of thiamine deficiency. (22136604)
2012
23
Guillain-Barre syndrome: first description of a snake envenomation aetiology. (22172144)
2012
24
Linkage of multiple sclerosis and guillain-barre syndrome: a population-based survey in isfahan, iran. (23198139)
2012
25
TH1 and TH2 response to Campylobacter jejuni antigen in Guillain-Barre syndrome. (21482924)
2011
26
Recognizing Guillain-Barre syndrome in preschool children. (21357832)
2011
27
Guillain-Barre syndrome, influenzalike illnesses, and influenza vaccination during seasons with and without circulating A/H1N1 viruses. (21652600)
2011
28
Keeping it simple: is there a need for the various subtyping of axonal forms of Guillain-Barre syndrome? (21551171)
2011
29
Guillain-Barre syndrome occurring during dengue fever. (22480104)
2011
30
The Diagnostic, Prognostic, and differential value of enhanced MR imaging in Guillain-Barre syndrome. (21596802)
2011
31
Guillain-Barre syndrome and adjuvanted pandemic influenza A (H1N1) 2009 vaccine: multinational case-control study in Europe. (21750072)
2011
32
Genomic characterization of the Guillain-Barre syndrome-associated Campylobacter jejuni ICDCCJ07001 Isolate. (21124772)
2010
33
This disorder has some nerve: chronic pain in Guillain-Barre syndrome. (20861453)
2010
34
Celiac disease associated with recurrent Guillain Barre syndrome. (21048269)
2010
35
Guillain-Barre syndrome: a clinical study in King Chulalongkorn Memorial Hospital. (20973317)
2010
36
A case of diabetic neuropathy combined with Guillain-Barre syndrome. (20526398)
2010
37
Axonal variant of Guillain-Barre syndrome associated with campylobacter infection in Bangladesh. (20625176)
2010
38
Guillain-Barre syndrome presenting as epiglottitis in a child. (20304295)
2010
39
Dry beriberi mimicking the Guillain-Barre syndrome. (19608771)
2009
40
Hairy cell leukemia presenting with Guillain-Barre syndrome. (17487755)
2007
41
AMSAN variant of Guillain Barre syndrome progressing to chronic inflammatory demyelinating polyneuropathy in a patient with Marfan's syndrome and pulmonary tuberculosis. (16515122)
2005
42
Fas polymorphisms are associated with the presence of anti-ganglioside antibodies in Guillain-Barre syndrome. (15748958)
2005
43
Circulating tumour necrosis factor alpha & soluble TNF receptors in patients with Guillain-Barre syndrome. (14609050)
2003
44
Guillain-Barre syndrome in patient with Burkitt's lymphoma and type 2 diabetes mellitus. (11928901)
2001
45
Severe cardiovascular autonomic dysfunction in a patient with Guillain-Barre syndrome: a case report. (11269930)
2000
46
Guillain-Barre syndrome following 2-chlorodeoxyadenosine treatment for Hairy Cell Leukemia. (11342351)
2000
47
Differential diagnosis and treatment of conversion disorder and Guillain-Barre syndrome. (1934840)
1991
48
Laseque's sign--an important bedside diagnostic sign in acute polyradiculopathy (Guillain-Barre syndrome). (451640)
1979
49
The pattern of Guillain-Barre syndrome (acute polyradiculopathy) in Singapore--a critical analysis of 46 cases. (517998)
1979
50
GUILLAIN-BARRE SYNDROME ASSOCIATED WITH ULCEROGLANDULAR TULAREMIA. (14215606)
1964

Variations for Guillain-Barre Syndrome

About this section

Expression for genes affiliated with Guillain-Barre Syndrome

About this section
Search GEO for disease gene expression data for Guillain-Barre Syndrome.

Pathways for genes affiliated with Guillain-Barre Syndrome

About this section

Pathways related to Guillain-Barre Syndrome according to GeneCards Suite gene sharing:

(show all 29)
idSuper pathwaysScoreTop Affiliating Genes
19.5MBP, MPZ, PMP22
29.3TNF, TNFRSF1A, TNFRSF1B
39.3TNF, TNFRSF1A, TNFRSF1B
4
Show member pathways
9.3TNF, TNFRSF1A, TNFRSF1B
5
Show member pathways
9.3TNF, TNFRSF1A, TNFRSF1B
69.3TNF, TNFRSF1A, TNFRSF1B
7
Show member pathways
9.3TNF, TNFRSF1A, TNFRSF1B
89.3TNF, TNFRSF1A, TNFRSF1B
99.3CD40LG, TNF, TNFRSF1A
109.0CD40LG, TNFRSF1A, TNFRSF1B
11
Show member pathways
8.8CD40LG, TNF, TNFRSF1A, TNFRSF1B
12
Show member pathways
8.8CD40LG, TNF, TNFRSF1A, TNFRSF1B
138.7HLA-DQA1, HLA-DQB1, HLA-DRB1
148.7HLA-DQA1, HLA-DQB1, HLA-DRB1
15
Show member pathways
8.7HLA-DQA1, HLA-DQB1, HLA-DRB1
16
Show member pathways
8.7HLA-DQA1, HLA-DQB1, HLA-DRB1
178.7HLA-DQA1, HLA-DQB1, HLA-DRB1
188.5CD40LG, CD79A, TNF, TNFRSF1A, TNFRSF1B
198.4HLA-DQA1, HLA-DQB1, HLA-DRB1, TNF
20
Show member pathways
8.2CD40LG, HLA-DQA1, HLA-DQB1, HLA-DRB1
218.0HLA-DQA1, HLA-DQB1, HLA-DRB1, TNF, TNFRSF1A
22
Show member pathways
8.0HLA-DQA1, HLA-DQB1, HLA-DRB1, TNF, TNFRSF1A
238.0HLA-DQA1, HLA-DQB1, HLA-DRB1, TNF, TNFRSF1A
24
Show member pathways
7.9CD40LG, HLA-DQA1, HLA-DQB1, HLA-DRB1, TNF
25
Show member pathways
7.8CD40LG, HLA-DQA1, HLA-DQB1, TNF, TNFRSF1A, TNFRSF1B
26
Show member pathways
7.8CD79A, HLA-DQA1, HLA-DQB1, HLA-DRB1, TNF, TNFRSF1A
277.7CD40LG, HLA-DQA1, HLA-DQB1, HLA-DRB1, MPZ
28
Show member pathways
7.5CD40LG, HLA-DQA1, HLA-DQB1, HLA-DRB1, TNF, TNFRSF1A
29
Show member pathways
6.7CD40LG, CD79A, HLA-DQA1, HLA-DQB1, HLA-DRB1, TNF

GO Terms for genes affiliated with Guillain-Barre Syndrome

About this section

Cellular components related to Guillain-Barre Syndrome according to GeneCards Suite gene sharing:

(show all 11)
idNameGO IDScoreTop Affiliating Genes
1compact myelinGO:004321810.6MBP, PMP22
2membrane raftGO:00451219.4CD79A, TNF, TNFRSF1A, TNFRSF1B
3MHC class II protein complexGO:00426139.3HLA-DQA1, HLA-DQB1, HLA-DRB1
4integral component of lumenal side of endoplasmic reticulum membraneGO:00715569.3HLA-DQA1, HLA-DQB1, HLA-DRB1
5clathrin-coated endocytic vesicle membraneGO:00306699.3HLA-DQA1, HLA-DQB1, HLA-DRB1
6ER to Golgi transport vesicle membraneGO:00125079.3HLA-DQA1, HLA-DQB1, HLA-DRB1
7trans-Golgi network membraneGO:00325889.3HLA-DQA1, HLA-DQB1, HLA-DRB1
8transport vesicle membraneGO:00306589.2HLA-DQA1, HLA-DQB1, HLA-DRB1
9endocytic vesicle membraneGO:00306669.1HLA-DQA1, HLA-DQB1, HLA-DRB1
10integral component of plasma membraneGO:00058877.4CD40LG, CD79A, HLA-DQA1, MPZ, TNF, TNFRSF1A
11plasma membraneGO:00058865.4CD40LG, CD79A, HLA-DQA1, HLA-DQB1, HLA-DRB1, MBP

Biological processes related to Guillain-Barre Syndrome according to GeneCards Suite gene sharing:

(show all 14)
idNameGO IDScoreTop Affiliating Genes
1response to mercury ionGO:004668910.5ALB, MBP
2regulation of establishment of endothelial barrierGO:190314010.4TNF, TNFRSF1A
3death-inducing signaling complex assemblyGO:007155010.4TNF, TNFRSF1A
4positive regulation of membrane protein ectodomain proteolysisGO:005104410.3TNF, TNFRSF1B
5positive regulation of ceramide biosynthetic processGO:200030410.2TNF, TNFRSF1A
6regulation of immunoglobulin secretionGO:005102310.2CD40LG, TNF
7defense responseGO:00069529.8HP, TNF, TNFRSF1A
8intrinsic apoptotic signaling pathway in response to DNA damageGO:00086309.8TNF, TNFRSF1A, TNFRSF1B
9tumor necrosis factor-mediated signaling pathwayGO:00332099.3CD40LG, TNF, TNFRSF1A, TNFRSF1B
10interferon-gamma-mediated signaling pathwayGO:00603339.2HLA-DQA1, HLA-DQB1, HLA-DRB1
11inflammatory responseGO:00069548.8CD40LG, TNF, TNFRSF1A, TNFRSF1B
12antigen processing and presentation of exogenous peptide antigen via MHC class IIGO:00198868.6HLA-DQA1, HLA-DQB1, HLA-DRB1
13immune responseGO:00069558.3HLA-DQA1, HLA-DQB1, MBP, TNFRSF1A, TNFRSF1B
14T cell costimulationGO:00312957.9CD40LG, HLA-DQA1, HLA-DQB1, HLA-DRB1

Molecular functions related to Guillain-Barre Syndrome according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1MHC class II receptor activityGO:00323959.9HLA-DQA1, HLA-DQB1
2antioxidant activityGO:00162099.7ALB, HP
3peptide antigen bindingGO:00426058.7HLA-DQA1, HLA-DQB1, HLA-DRB1

Sources for Guillain-Barre Syndrome

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
25GTR
26HGMD
27HMDB
28ICD10
29ICD10 via Orphanet
30ICD9CM
31IUPHAR
32KEGG
35MedGen
37MeSH
38MESH via Orphanet
39MGI
42NCI
43NCIt
44NDF-RT
47NINDS
48Novoseek
50OMIM
51OMIM via Orphanet
55PubMed
56QIAGEN
61SNOMED-CT via Orphanet
65Tumor Gene Family of Databases
66UMLS
67UMLS via Orphanet